Tirzepatide
Also called Mounjaro, Zepbound, GIP/GLP-1
A once-weekly injection that pulls two levers at the same time.
This one has been through full clinical trials and is an approved medicine somewhere in the world. The ranges below are drawn from those trials and from what the community reports using.
410,198 posts67,008 people9 communities
of community reporting analysed for this compound. That is the part you cannot find anywhere else — the trial data below it, you could look up yourself.
USA · FDA · Mounjaro / Zepbound
EU · EMA · Mounjaro
Canada · Mounjaro
Japan
China
- Body composition
- Fat loss & metabolic
The quick answer
A once-weekly injection that pulls two levers at the same time. GLP-1 is the one everyone knows - appetite down, stomach empties slower, you feel full sooner and stay full longer. GIP is the second, and it changes how fat cells handle what arrives and improves how the body responds to insulin. Semaglutide pulls one lever. This pulls two, and that is the whole reason the numbers are bigger.
What it is not
Not a compound you can stop and keep the result from. Appetite returns when it leaves.
Why people use it
Appetite quiets down, often noticeably in the second or third week. Food noise - the constant background negotiation about eating - is the thing people say they miss least. Blood sugar and lipids usually improve alongside the weight.
What people report using
These are ranges other people have reported running. They are here so you can see what has actually been done — they are not medical advice and not a recommendation for you.
People report running this anywhere from 10mg to 15mg, once weekly.Where somebody sits in that range depends on what they are using it for and what they are starting from — the low end is a deliberate choice a lot of people make, not a half-hearted version of the high end.
Fat loss & metabolic
- How often
- Once weekly
- Route
- subcutaneous
- Where this comes from
- Approved medicine
Appetite quiet inside the first week or two.
What to expect, and when
Week 1-2: mostly your body meeting the compound - some nausea, some fatigue. Week 2-3: appetite change lands, and this is the part people notice. Week 4-8: the scale follows. Month 3-6: where the results people post actually come from. The people who quit at week four almost always quit before it started working.
Side effects, and what people do about them
Nausea is the most reported, though less than on semaglutide - in an analysis of 29,172 people posting about these two, nausea came up for 28.6% of tirzepatide users against 39.4% for semaglutide, and vomiting 11.1% against 18.0%. It clusters around dose increases rather than lasting forever. Sitting at a step longer before climbing is the lever most people use.
Go deeper
Open these only if you want them.
How it actually works
Dual GIP and GLP-1 receptor agonist.
More on the evidence
Approved dual GIP/GLP-1 agonist. Large phase 3 programme.
What people report, in full
The community's own word for what tirzepatide does is "food noise" - the constant background negotiation about eating - and the most consistently reported thing is that it goes quiet. People describe deciding not to finish a plate without it feeling like a decision. That is the effect people come back to describe, more than the number on the scale.
The practical conventions are unusually consistent. Titrate slower than the schedule allows: the people who report a miserable first month are nearly always the ones who moved up on the calendar rather than on how they felt, and the people who did well routinely say they stayed at a lower step longer and landed lower overall than they expected to need. Eat protein first, because appetite is now a limited budget and it gets spent on whatever is in front of you. Constipation is the complaint that outlasts the nausea, and fibre and water are what the community reaches for. Sulphur burps come up constantly and are treated as a sign of eating too much fat in one sitting.
Muscle loss is the theme experienced users raise with newer ones unprompted - resistance training and protein are described as non-negotiable rather than optional, and the regret people voice at the far end is usually about that rather than about the drug. A reproductive signal shows up in community reports that is not in the labelling: intermenstrual bleeding, heavier periods and irregular cycles, each at roughly one percent of reports. Worth knowing if you are a woman running this.
Sources and review
Most of what is useful about these compounds comes from people who have used them, not from trials. These are published analyses of what communities reported. We did not read the posts ourselves and we do not claim to.
410,198 posts67,008 people9 communities
Reports from 2019-05 to 2025-06
Sehgal NKR, et al. Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities. medRxiv 2026 / Nature Health.
Preprint then journal. Self-selected posters, not a cohort.
SURMOUNT-1 — Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022. DOI 10.1056/NEJMoa2206038. PMID 35658024.16.0% to 22.5% mean weight loss in adults with obesity or overweight.
SURPASS-2 — Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021. DOI 10.1056/NEJMoa2107519. PMID 34170647.Superior A1C and body-weight reduction against injectable semaglutide.
These references were located by literature search and recorded as the primary sources behind this record. The publishers block automated retrieval, so they are pointers to the right papers rather than quotations we have checked line by line. They are replaced as we read them properly.
Last reviewed 2026-09-08.
People also look at
Still not sure?
Ask it the way you would ask a person. Follow-up questions are the point — it remembers what you already said.
Ask about Tirzepatide